Schedule III: The Rule Text, the Hearing, and What Actually Moved

On April 28, 2026, a document entered the Federal Register and pulled part of the cannabis plant out of Schedule I. Not the part most Americans smoke.

The coverage that followed flattened a two-track action into one headline. There is a cannabis Schedule III rule that is already binding, and there is a separate proposal that went to a hearing in the summer and still has no decision attached to it. Telling the two apart is the whole subject.

What the cannabis Schedule III rule actually says

The document is Federal Register 2026-08176, printed at 91 FR 22714, and its action line runs to two words: final rule. The Acting Attorney General placed FDA-approved drug products containing marijuana into Schedule III of the Controlled Substances Act, and placed marijuana held under a state medical marijuana license there alongside them.

That second category is wider than most reporting suggested. It reaches marijuana, marijuana extracts and delta-9 THC falling outside the hemp definition, wherever they sit under a state-issued license to manufacture, distribute or dispense marijuana for medical purposes. A licensed medical operator in Ohio and a pharmaceutical manufacturer in New Jersey ended up in the same schedule on the same morning.

The effective date was the publication date. No phase-in, no transition year.

The one sentence that draws the border

Everything people get wrong about this rule is answered by a single line inside it. Any form of marijuana other than an FDA-approved drug product, or marijuana subject to a state medical marijuana license, remains a Schedule I controlled substance.

That sentence is doing enormous work. Unlicensed bulk marijuana stays in Schedule I even when it is grown to be turned into an FDA-approved medicine, and it only changes status once it has been incorporated into the finished product. Adult-use cannabis was never in the room.

Why the final rule was written this way

The reasoning is not pharmacological. The rule states that the action is required to carry out United States obligations under the Single Convention on Narcotic Drugs of 1961, the treaty that has shaped American drug scheduling since before most of this industry existed.

That explains the shape of the carve-outs. A treaty written around medical and scientific supply can accommodate licensed medicine. It cannot accommodate a recreational market. So the DEA rescheduling final rule of 2026 sorted the plant by paperwork, not by chemistry, and built an expedited registration route so state medical licensees could get federal registration without joining the back of a queue.

One detail almost nobody covered is worth knowing if you are a patient. The rule accepts a state certification as sufficient to dispense. A federal prescription is not required, which means the medical programs people already use do not have to be rebuilt around a pharmacy model.

Why there is no Schedule III hearing outcome yet

A second document published the same day, 2026-08177, is a notice rather than a rule. It announced that the DEA would hold a hearing on the proposed rescheduling of marijuana as a whole, beginning June 29, 2026.

This is the proceeding that would move everything else. It has a long history: a proposed rule from May 2024, a hearing noticed that August, then the whole thing terminated and restarted in 2026 to get it moving faster.

The hearing ran at DEA headquarters in Arlington from June 29 to July 15, in front of Chief Administrative Law Judge Derek Julius. The DEA argued in its own final brief that marijuana no longer meets the statutory test for Schedule I. Opposing states argued the other way. Post-hearing briefs landed in August, and the judge will now weigh them and issue a recommendation that goes to the DEA administrator, who makes the final call.

No recommendation has been made public as of this writing. Anyone quoting a Schedule III hearing outcome is describing something that has not happened.

It is worth being clear about what a broader move would and would not deliver, because the expectations attached to it have grown well past the paperwork. Schedule III would extend the tax relief below to the whole licensed industry and would loosen the research restrictions that have kept American cannabis science a decade behind the market. It would not legalize possession, would not open interstate commerce, and would not stop a federal agency from treating a positive test as disqualifying. Every state line on the map stays exactly where it is.

The unexamined day is a wasted opportunity. Reflect on what you did, what you learned, and how you can improve.

John Dewey

Is marijuana still Schedule 1?

Yes, by default, with two exceptions. Two categories sit in Schedule III: an FDA-approved drug product containing marijuana, and marijuana held under a state medical marijuana license. Everything else stays in Schedule I, which covers adult-use cannabis bought in a licensed recreational store and any unlicensed marijuana, bulk material included.

If you buy in a state-legal recreational shop, nothing about your purchase changed in April. If you buy on a medical card from a licensed operator, the product in your hand sits in a different federal schedule than it did in March.

What changes at the register, and what does not

Taxes move first. Section 280E blocks ordinary business deductions for anyone trafficking in Schedule I or Schedule II substances, and it is keyed to those two schedules alone. Treasury and the IRS confirmed in April that rescheduling generally removes section 280E as a bar to claiming deductions and credits. For a licensed medical operator that is the difference between a viable business and a decorative one.

Banking did not move at all. The SAFE Banking Act was reintroduced in June 2026, which is the eighth time this reform has come around, and the Senate has never passed it. Most of the industry still runs on cash.

Nothing in the April rule legalizes anything. Schedule III is a control level, not a permission slip. Federal registration is still required to handle the products it covers, and state law still decides what happens on the ground.

What a breeder notices in a document like this

Forty years of this business teaches you to read scheduling documents in a particular way, because the definitions almost never describe the plant.

Look again at that split. The same cultivar, the same genetics, the same terpene profile, sorted into two different federal schedules by whose license it sits under. A clone taken from one mother plant is Schedule III in a medical facility and Schedule I in the recreational room next door. Nothing about the biology moved. The paperwork did.

We have watched this from the other side since the 1980s, when Derry was carrying landrace genetics back from Afghanistan and the Himalayas and the legal category for what he was doing did not exist anywhere. The plant kept behaving like a plant while governments rewrote what it was called. Two examples of that continuity sit in our current catalog:

• Critical Kush, a Critical Mass and OG Kush cross bred for heavy resin and a genuinely sedating finish.
• Northern Lights, a strain that was already a fixture of medical use decades before any regulator agreed such a thing existed.

Both were stabilized long before the federal government had a category for either of them, and neither changed in April.

That is the practical case for growing your own, and it has nothing to do with defiance. A plant you grew has a documented lineage you can name. Its legal status depends on your state, which you can read, and not on which license the shelf it came from was operating under.

Where this leaves you

Medical cannabis under a state license is Schedule III and has been since April. Everything else is Schedule I. The proceeding that could change that was argued in July, briefed in August, and is sitting with a judge who has given no timeline.

Watch for the recommendation, then watch for what the administrator does with it, because the second step is where this actually gets decided. Until then, the honest version is that a narrow, treaty-shaped door opened for licensed medicine, and the rest of the plant is exactly where it was.

Barney's Farm has been developing premium cannabis genetics since the 1980s, with over 40 Cannabis Cup wins. Explore our full seed catalog and find strains bred for every climate and skill level.